A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia

Current Medicinal Chemistry

Volumn 19, Issue 31, 2012, Pages 5294-5318

  Robak, P ^a,b   Robak, T ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

AG013736; AVL 292; Axitinib; Bafetinib; BAY 61 3606; Bosutinib; Btk; C 61; CAL 101; CLL; Cyclin dependent kinases; Dasatinib; Flavopiridol; Fostamatinib; GDC 0834; Ibrutinib; Lyn; Multikinase inhibitors; NHL; Pazopanib; PCI 32765; PI3K; PP2; R406; SKI 606; Sorafenib; SU6656; Sunitinib; Syk; TKI258; Tyrosine kinase inhibitors; Vandetanib

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ALPHA CYANO BETA HYDROXY BETA METHYL N (2,5 IBROMOPHENYL) PROPENAMIDE; AVL 101; AVL 263; AVL 291; AXITINIB; B LYMPHOCYTE RECEPTOR; BAFETINIB; BENDAMUSTINE; BOSUTINIB; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; CELL SURFACE RECEPTOR; DASATINIB; DINACICLIB; DOVITINIB; FLAVOPIRIDOL; FOSTAMATINIB; GDC 0834; GSK 1059615; IBRUTINIB; IDELALISIB; IMATINIB; MDL 107826A; N [3 [6 [4 (1,4 DIMETHYL 3 OXOPIPERAZIN 2 YL)PHENYLAMINO] 4 METHYL 5 OXO 4,5 DIHYDROPYRAZIN 2 YL] 2 METHYLPHENYL] 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE 2 CARBOXAMIDE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OFATUMUMAB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PICEATANNOL; PICTILISIB; PKI 402; PROTEIN KINASE; PROTEIN KINASE SYK INHIBITOR; PRT 060318; RITUXIMAB; ROSCOVITINE; SORAFENIB; STEMOLECULE; SUNITINIB; U 11248; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ARTICLE; BIOLOGICAL ACTIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; ENZYME ACTIVE SITE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; SIGNAL TRANSDUCTION; WALDENSTROEM MACROGLOBULINEMIA;

CYCLIN-DEPENDENT KINASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; SRC-FAMILY KINASES;

EID: 84870413230     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803833371     Document Type: Article

References (220)

1. Redaelli, A.; Laskin, B.L.; Stephens, J.M.; Botteman, M.F.; Pashos, C.L. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care., 2004, 13, 279-267.
2. Watson, L.; Wyld, P.; Catovsky, D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur. J. Haematol., 2008, 81, 253-258.
3. Robak, T.; Kasznicki, M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia, 2002, 16, 1015-1027.
4. CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl. Cancer Inst., 1999, 91, 861-868.
5. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G.A.l; Larson, R.A.; Cheson, B.D.; Schiffer, C.A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med., 2000, 343,1750-1757.
6. Robak, T.; Bloński, J.Z.; Kasznicki, M.; Blasińska- Morawiec, M.; Krykowski, E.; Dmoszyńska, A.; Mrugala-Spiewak, H.; Skotnicki, A.B.; Nowak, W.; Konopka, L.; Ceglarek, B.; Maj, S.; Dwilewicz-Trojaczek, J.; Hellmann, A.; Urasiński, I.; Zdziarska, B.; Kotlarek-Haus, S.; Potoczek, S.; Grieb, P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood, 2000, 96, 2723-2729.
7. Eichhorst, B.F.; Busch, R.; Hopfinger, G.; Pasold, R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jäger, U.; Bergmann, M.; Stilgenbauer, S.; Schweighofer, C.; Wendtner, C.M.; Döhner, H.; Brittinger, G.; Emmerich, B.; Hallek, M.; German. CLL Study Group Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2006,107, 885-891.
8. Robak, T.; Jamroziak, K.; Gora-Tybor, J.; Stella-Holowiecka, B.; Konopka, L.; Ceglarek, B.; Warzocha, K.; Seferynska, I.; Piszcz, J.; Calbecka, M.; Kostyra, A.; Dwilewicz-Trojaczek, J.; Dmoszyńska, A.; Zawilska, K.; Hellmann, A.; Zdunczyk, A.; Potoczek, S.; Piotrowska, M.; Lewandowski, K.; Blonski, J.Z. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic oeukemia: A phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J. Clin. Oncol., 2010, 28,1861-1869.
9. Hallek, M.;Fischer, K.; Fingerle-Rowson, G.; Fink, A.M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Grünhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P.L.; Caligaris-Cappio, F.; Seymour, J.F.; Berrebi, A.; Jäger, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C.M.; Eichhorst, B.F.; Staib, P.; Bühler, A.; Winkler, D.; Zenz, T.; Böttcher, S.; Ritgen, M.; Mendila, M.; Kneba, M.; Döhner, H.; Stilgenbauer, S. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 2010, 376, 1164-1174.
10. Robak, T.; Dmoszynska, A.; Solal-Céligny, P.; Warzocha, K.; Loscertales, J.; Catalano, J.; Afanasiev, B.V.; Larratt, L.; Geisler, C.H.; Montillo, M.; Zyuzgin, I.; Ganly, P.S.; Dartigeas, C.; Rosta, A.; Maurer, J.; Mendila, M.; Saville, M.W.; Valente, N.; Wenger, M.K.; Moiseev, S.I. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28, 1756-1765.
11. Smolewski, P.; Robak,T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr. Mol. Med., 2011, 11, 633-649.
12. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nature Rev Drug Discovery, 2002,1, 309-315.
13. Hillmen, P. Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future. J. Clin. Oncol. 2012, 30, 469-470.
14. Uckun, F.M.; Qazi, S. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas. Expert Rev Anticancer Ther., 2010,10,1407-1418.
15. Balakrishnan, K.; Gandhi, V. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs, 2012, 21, 409 - 423.
16. Robak, T.; Robak, E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin. Investig. Drugs. 2012, 21, 921-47.
17. Gora-Tybor, J.; Robak, T. Targeted drugs in chronic myeloid leukemia. Curr. Med. Chem., 2008, 15, 3036-3151.
18. Wickremasinghe, R.G.; Prentice, A.G.; Steele, A.J. Aberrantly activated antiapoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identification of novel therapeutic targets. Br. J. Haematol., 2011, 153, 545-556.
19. Packham, G.; Stevenson, F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin. Cancer Biol., 2010, 20, 391-399.
20. Agathangelidis, A.; Darzentas, N.; Hadzidimitriou, A.; Brochet, X.; Murray,F.; Yan.; X.J.;Davis, Z.; van Gastel-Mol, E.J.; Tresoldi, C.; Chu, C.C.; Cahill, N.; Giudicelli, V.; Tichy, B.; Pedersen, L.B.; Foroni, L.; Bonello, L.; Janus, A.; Smedby, K.; Anagnostopoulos, A.; Merle-Beral, H.; Laoutaris, N.; Juliusson, G.; di Celle, P.F.; Pospisilova, S.; Jurlander, J.; Geisler, C.; Tsaftaris, A.; Lefranc, M.P.; Langerak, A.W.; Oscier, D.G.; Chiorazzi, N.; Belessi, C.; Davi, F.; Rosenquist, R.; Ghia, P.; Stamatopoulos, K. Stereotyped B-cell receptors inone-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012,119, 4467-4475.
21. Stamatopoulos, K.; Belessi, C.; Moreno, C.; Boudjograh, M.; Guida, G.; Smilevska, T.; Belhoul, L.; Stella, S.; Stavroyianni, N.; Crespo, M.; Hadzidimitriou, A.; Sutton, L.; Bosch, F.; Laoutaris, N.; Anagnostopoulos, A.; Montserrat, E.; Fassas, A.; ighiero, G.; Caligaris-Cappio, F.; Merle-Béral, H.; Ghia, P.; Davi, F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007,109, 259-270.
22. Chu, C.C.; Catera, R.; Hatzi, K.; Yan, X.J.; Zhang, L.; Wang, X.B.; Fales, H.M.; Allen, S.L.; Kolitz, J.E.; Rai, K.R.; Chiorazzi, N. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010,115, 3907-3915.
23. Herman, S.E.; Gordon, A.L.; Hertlein, E.; Ramanunni, A.; Zhang, X.; Jaglowski, S.; Flynn, J.; Jones, J.; Blum, K.A.; Buggy, J.J.; Hamdy, A.; Johnson, A.J.; Byrd, J.C. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI- 32765., Blood, 2011, 117, 6287-6296.
24. Uckun, F.M.; Qazi, S. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity. Expert Opin Ther Pat., 2010, 20, 1457-1470.
25. Conley, M.E.; Dobbs, A.K.; Farmer, D.M.; Kilic, S.; Paris, K.; Grigoriadou, S.; Coustan-Smith, E.; Howard, V.; Campana, D. Primary B cell immunodeficiencies: comparisons and contrasts. Annu. Rev. Immunol., 2009, 27, 199-227.
26. Winer, E.S.; Ingham, R.R.; Castillo, J.J. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs. 2012, 21, 355-361.
27. Davis, R.E.; Ngo, V.N.; Lenz, G.; Tolar, P.; Young, R.M.; Romesser, P.B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A.L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J.K.; Thomas, C.J.; Rosenwald, A.; Ott, G.; Muller- Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Johnson, N.A.; Rimsza, L.M.; Campo, E.; Jaffe, E.S.; Wilson, W.H.; Delabie, J.; Smeland, E.B.; Fisher, R.I.; Braziel, R.M.; Tubbs, R.R.; Cook, J.R.; Weisenburger, D.D.; Chan, W.C.; Pierce, S.K.; Staudt, L.M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 2010, 463, 88-92.
28. Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A.; Buggy, J.J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U S A., 2010,107,13075-13080.
29. Ponader, S.; Chen, S.S.; Buggy, J.J.; Balakrishnan, K.; Gandhi, V.; Wierda, W.G., Keating, M.J.; O'Brien, S.; Chiorazzi, N.; Burger, J.A. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 2012,119,1182-1189.
30. Rooij, M.F.; Kuil, A.; Geest, C.R.; Eldering, E.; Chang, B.Y.; Buggy, J.J.; Pals, S.T.; Spaargaren, M. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 2012, 119, 2590-2594.
31. Advani, R.; Sharman, J.; Smith, S.T, Boyd, T. E.; Grant, B.W.; Kolibaba, K.S.; Furman, R.R.; Buggy, J.J.; Loury, D. J.; Hedrick, E.; Izumi, R.; Hamdy, A. M.; Fowler, N.H. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: Final results from a Phase I study. Ann. Oncol., 2011, 22(suppl 4),135-137.
32. O'Brien, S.; Burger, J.A.; Coutre, S.E.; Sharman, J. P.; Furman, R. R.; Flinn, I.W.; Grant, B.; Richards, D.; Heerema, N.; Johnson, A.J.; Izumi, R.; Hamdy, A.; Blum, K. A.; Byrd, J. C. The Btk Inhibitor PCI-32765 is highly active and tolerable in patients with poor-risk CLL: Interim results from a Phase Ib/II study. Ann. Oncol., 2011, 22(suppl 4),123-124.
33. Mahajan, S.; Ghosh, S.; Sudbeck, E.A.; Zheng, Y.; Downs, S.; Hupke, M.; Uckun, F.M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13[alpha-cyano-betahydroxy-beta- methyl-N-(2,5-dibromophenyl) propenamide]. J. Biol. Chem., 1999, 274, 9587-9599.
34. Uckun, F.; Dibirdik, I.; Sarkissian, A.; Qazi, S. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. Arzneimittelforschung, 2011,61, 252-259.
35. Mócsai, A.; Ruland, J.; Tybulewicz, V.L. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev Immunol., 2010,10,387-402.
36. Young, R.M.; Hardy, I.R.; Clarke, R.L.; Lundy, N.; Pine, P.; Turner, B.C.; Potter, T.A.; Refaeli, Y. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood, 2009,113, 2508-2516.
37. Baudot, A.D.; Jeandel, P.Y.; Mouska, X.; Maurer, U.; Tartare-Deckert, S.; Raynaud, S.D.; Cassuto, J.P.; Ticchioni, M.; Deckert, M. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene, 2009, 28, 3261-3273.
38. Turner, M.; Schweighoffer, E.; Colucci, F.; Di Santo, J.P.; Tybulewicz, V.L. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol. Today, 2000, 21,148-154.
39. Geahlen, R.L. Syk and pTyr'd: Signaling through the B cell antigen receptor. Biochim. Biophys. Acta., 2009,1793,1115-1127.
40. Irish, J.M.; Czerwinski, D.K.; Nolan, G.P.; Levy, R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor infiltrating nonmalignant B cells. Blood, 2006, 108, 3135-3142.
41. Buchner, M.; Fuchs, S.; Prinz, G.; Pfeifer, D.; Bartholomé, K.; Burger, M.; Chevalier, N.; Vallat, L.; Timmer, J.; Gribben, J.G.; Jumaa, H.; Veelken, H.; Dierks, C.; Zirlik, K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res., 2009, 69, 5424-5432.
42. Quiroga, M.P.; Balakrishnan, K.; Kurtova, A.V.; Sivina, M.; Keating, M.J.; Wierda, W.G.; Gandhi, V.; Burger, J.A. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood, 2009, 114, 1029-1037.
43. Sweeny, D.J.; Li, W.; Grossbard, E.; Lau, D.T. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica, 2010, 40, 415-4123.
44. Chen, L.; Monti, S.; Juszczynski, P.; Daley, J.; Chen, W.; Witzig, T.E.; Habermann, T.M.; Kutok, J.L.; Shipp, M.A. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood, 2008,111, 2230-2237.
45. Zhu, Y.; Herlaar, E.; Masuda, E.S., Burleson, G.R.; Nelson, A.J.; Grossbard, E.B.; Clemens, G.R. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicol. Appl. Pharmacol., 2007, 221, 268-277.
46. Mocsai, A.; Ruland, J.; Tybulewicz. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol., 2010,10,387-402.
47. Braselmann, S.; Taylor, V.; Zhao, H.; Wang, S.; Sylvain, C.; Baluom, M.; Qu, K.; Herlaar, E.; Lau, A.; Young, C.; Wong, B.R.; Lovell, S.; Sun, T.; Park, G.; Argade, A.; Jurcevic, S.; Pine, P.; Singh, R.; Grossbard, E.B.; Payan, D.G.; Masuda, E.S. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther., 2006, 319, 998-1008.
48. Suljagic, M.; Longo, P.G.; Bennardo, S.; Perlas, E.; Leone, G.; Laurenti, L.; Efremov, D.G.The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E{micro}- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood, 2010,116,4894-4905.
49. Sweeny, D.J.; Li, W.; Clough, J.; Bhamidipati, S.; Singh, R.; Park, G.; Baluom, M.; Grossbard, E.; Lau, D.T. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab. Dispos., 2010, 38, 1166-1176.
50. Friedberg, J.W.; Sharman, J.; Sweetenham, J.; Johnston, P.B.; Vose, J.M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J.P.; Cripe, L.D.; Gregory, S.A.; Sterba, M.P.; Lowe, A.M.; Levy, R.; Shipp, M.A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 2010, 115, 2578-2585.
51. Reilly, M.P.; Sinha, U.; André, P.; Taylor, S.M.; Pak, Y.; Deguzman, F.R.; Nanda, N.; Pandey, A.; Stolla, M.; Bergmeier, W.; McKenzie, S.E. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood, 2011,117, 2241-2246.
52. Wolter, F.; Clausnitzer, A.; Akoglu, B.; Stein, J. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J. Nutr., 2002, 132, 298-302.
53. Lu, Z.X.; Polya, G.M. Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol. Planta Med., 1998, 64, 195-199.
54. Ovesná, Z.; Kozics, K.; Bader, Y.; Saiko, P.; Handler, N.; Erker, T.; Szekeres, T. Antioxidant activity of resveratrol, piceatannol and 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene in three leukemia cell lines. Oncol. Rep. 2006,16, 617-624.
55. Azmi, A.S.; Bhat, S.H.; Hadi, S.M. Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett., 2005, 579, 3131-3135.
56. Gururajan, M.; Jennings, C.D.; Bondada, S. Cutting edge: constitutive B cell receptor signaling is critical. J. Immunol., 2006,176, 5715-5719.
57. Uckun, F.M.; Qazi, S.; Ma, H.; Tuel-Ahlgren, L.; Ozer, Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/ lymphoma cells exposed to oxidative stress. Proc. Natl Acad. Sci. USA, 2010,107, 2902-2907.
58. Uckun, F.M.; Qazi, S.; Ozer, Z.; Garner, A.L.; Pitt, J.; Ma, H.; Janda, K.D. Inducing apoptosis in chemotherapy- resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br. J. Haematol. 2011,153, 741-152.
59. Uckun, F.M.; Dibirdik, I.; Qazi, S. Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK). Radiat Res. 2010, 174, 526-531.
60. Uckun, F.M.; Ek, R.O.; Jan, S.T.; Chen, C.L.; Qazi, S. Targeting SYK kinase- dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Haematol., 2010, 149, 508-517.
61. Niiro, H.; Clark, E.A. Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2002, 2, 945-956.
62. Contri, A.; Brunati, A.M.; Trentin, L.; Cabrelle, A.; Miorin, M.; Cesaro, L.; Pinna, L.A.; Zambello, R.; Semenzato, G.; Donella-Deana, A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest., 2005,115, 369-378.
63. Wiestner, A.; Rosenwald, A.; Barry, T.S.; Wright, G.; Davis, R.E.; Henrickson, S.E.; Zhao, H.; Ibbotson, R.E.; Orchard, J.A.; Davis, Z.; Stetler-Stevenson, M.; Raffeld, M.; Arthur, D.C.; Marti, G.E.; Wilson, W.H.; Hamblin, T.J.; Oscier, D.G.; Staudt, L.M. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood, 2003,101, 4944-4951.
64. Davis, R.E.; Ngo, V.N.; Lenz, G.; Tolar, P.; Young, R.M.; Romesser, P.B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A.L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J.K.; Thomas, C.J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Johnson, N.A.; Rimsza, L.M.; Campo, E.; Jaffe, E.S.; Wilson, W.H.; Delabie, J.; Smeland, E.B.; Fisher, R.I.; Braziel, R.M.; Tubbs, R.R.; Cook, J.R.; Weisenburger, D.D.; Chan, W.C.; Pierce, S.K.; Staudt, L.M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 2010, 463, 88-92.
65. Chow, K.U.; Nowak, D.; Hofmann, W.; Schneider, B.; Hofmann, W.K. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. Leukemia, 2005, 19, 1103-1105.
66. Aloyz, R.; Grzywacz, K.; Xu, Z.Y.; Loignon, M.; Alaoui-Jamali, M.A.; Panasci, L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia, 2004,18, 409-414.
67. Hebb, J.; Assouline, S.; Rousseau, C.; Desjardins, P.; Caplan, S.; Egorin, M.J.; Amrein, L.; Aloyz, R.; Panasci, L. A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. Cancer Chemother. Pharmacol., 2011, 68, 643-651.
68. Santos, F.P.; Kantarjian, H.; Cortes, J.; Quintas-Cardama, A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin. Investig Drugs, 2010,11, 1450-1465.
69. Kimura, S.; Naito, H.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Yokota, A.; Kamitsuji, Y.; Kawata, E.; Ashihara, E.; Nakaya, Y.; Naruoka, H.; Wakayama, T.; Nasu, K.; Asaki, T.; Niwa, T.; Hirabayashi, K.; Maekawa, T. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 2005,106, 3948-3954.
70. Niwa, T.; Asaki, T.; Kiura,S. NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. Anal. Chem. Insights., 2007, 2, 93-106.
71. Lee, M. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2. Biochem Biophys. Res. Commun., 2006, 350, 450-456.
72. Lee, M.; Ahn, J.H.; Eum, K.H. The Difference in Biological Properties between Parental and v-Ha-ras Transformed NIH3T3 Cells. Cancer Res. Treat., 2009, 41, 93-99.
73. Dos Santos, C.; Demur, C.; Bardet, V.; Prade-Houdellier, N.; Payrastre, B.; Récher, C. A critical role for Lyn in acute myeloid leukemia. Blood, 2008, 111, 2269-2279.
74. Congleton, J.; Macdonald, R.; Yen, A. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK dependent differentiation of myeloid leukemia cells. Leukemia, 2012, 26, 1180-1188.
75. Ke, J.; Chelvarajan, R.L.; Sindhava, V.; Robertson, D.A.; Lekakis, L.; Jennings, C.D.; Bondada, S. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol Cancer., 2009,8,132.
76. Contri, A.; Brunati, A.M.; Trentin, L.; Cabrelle, A.; Miorin, M.; Cesaro, L.; Pinna, L.A.; Zambello, R.; Semenzato, G.; Donella-Deana, A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest., 2005, 115, 369-378.
77. Ungefroren, H.; Sebens, S.; Groth, S.; Gieseler, F.; Fändrich, F. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors. Curr. Cancer Drug Targets., 2011,11, 524-535.
78. Blake, R.A.; Broome, M.A.; Liu, X.; Wu, J.; Gishizky, M.; Sun, L.; Courtneidge, S.A. SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling. Mol. Cell Biol., 2000, 20, 9018-9027.
79. Watzlawik, J.; Holicky, E.; Edberg, D.D.; Marks D.L.; Warrington, A.E.; Wright, B.R.; Pagano, R.E.; Rodriguez, M. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia, 2010, 58, 1782- 1793.
80. Dussault, N.; Simard, C.; Néron, S.; Côté, S. Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656. Blood Cells Mol. Dis., 2007,39,130-134.
81. Cuneo, K.C.; Geng, L.; Tan, J.; Brousal, J.; Shinohara, E.T.; Osusky, K.; Fu, A.; Shyr, Y.; Wu, H, Hallahan, D.E. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. Int. J. Radiat Oncol Biol. Phys. 2006, 64, 1197-1203.
82. Gururajan, M.;Jennings, C.D.; Bondada, S. Cutting edge: constitutive B cell receptor signaling is critical J. Immunol., 2006,176, 5715-5719.
83. Blagden, S.; de Bono, J. Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets, 2005, 6, 325- 335.
84. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 2006, 24, 1770-1783.
85. Senderowicz, A.M. Small-molecule cyclindependent kinase modulators. Oncogene, 2003, 22, 6609- 6620.
86. de Azevedo, W.F. Jr.; Canduri, F.; da Silveira, N.J. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochm. Biophys. Res. Commun., 2002, 293, 566-571.
87. Kitada, S.; Zapata, J.M.; Andreeff, M.; Reed, J.C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 2000, 96, 393-397.
88. Lin, T.S.; Ruppert, A.S.; Johnson, A.J.; Fischer, B.; Heerema, N.A.; Andritsos, L.A.; Blum, K.A.; Flynn, J.M.; Jones, J.A.; Hu, W.; Moran, M.E.; Mitchell, S.M.; Smith, L.L.; Wagner, A.J.; Raymond, C.A.; Schaaf, L.J.; Phelps, M.A.; Villalona-Calero, M.A.; Grever, M.R.; Byrd, J.C. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol., 2009, 27, 6012-6018.
89. Byrd, J.C.; Lin, T.S.; Dalton, J.T.; Wu, D.; Phelps, M.A.; Fischer, B.; Moran, M.; Blum, K.A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L.J.; Johnson, A.J.; Lucas, D.M.; Heerema, N.A.; Lozanski, G.; Young, D.C.; Suarez, J.R.; Colevas, A.D.; Grever, M.R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007,109, 399-404.
90. Flinn, I.W.; Byrd, J.C.; Bartlett, N.; Kipps, T.; Gribben, J.; Thomas, D.; Larson, R.A.; Rai, K.; Petric, R.; Ramon-Suerez, J.; Gabrilove, J.; Grever, M.R. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk. Res., 2005, 29, 1253-1257.
91. Christian, B.A.; Grever, M.R.; Byrd, J.C.; Lin, T.S. Flavopiridol in chronic lymphocytic leukemia: a concise review. Clin. Lymphoma Myeloma. 2009,9 Suppl 3, 79-85.
92. Byrd, J.C.; Peterson, B.L.; Gabrilove, J.; Odenike, O.M.; Grever, M.R.; Rai, K.; Larson, R.A. Cancer and Leukemia Group B. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin. Cancer Res., 2005, 11, 4176-4181.
93. Phelps, M.A.; Lin, T.S.; Johnson, A.J.; Hurh, E.; Rozewski, D.M.; Farley, K.L.; Wu, D.; Blum, K.A.; Fischer, B.; Mitchell, S.M.; Moran, M.E.; Brooker-McEldowney, M.; Heerema, N.A.; Jarjoura, D.; Schaaf, L.J.; Byrd, J.C.; Grever, M.R.; Dalton, J.T. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood, 2009, 113, 2637-2645.
94. Woyach, J.A.; Lozanski, G.; Ruppert, A.S.; Lozanski, A.; Blum, K.A.; Jones, J.A.; Flynn, J.M.; Johnson, A.J.; Grever, M.R.; Heerema, N.A.; Byrd, J.C. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia, 2012, 26,1442-1444.
95. Stephens, D.M.; Ruppert, A.S.; Blum, K.; Jones, J.; Flynn, J.M.; Johnson, A.J.; Ji, J.; Phelps, M.A.; Grever, M.R.; Byrd, J.C. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 2012, 97, 423-427.
96. Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Wiswell, D.; Seghezzi, W.; Paruch, K.; Dwyer, M.P.; Doll, R.; Nomeir, A.; Windsor, W.; Fischmann, T.; Wang, Y.; Oft, M.; Chen, T.; Kirschmeier, P.; Lees, E.M. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther., 2010, 9, 2344-2353.
97. Tong, W.G.; Chen, R.; Plunkett, W.; Siegel, D.; Sinha, R.; Harvey, R.D.; Badros, A.Z.; Popplewell, L.; Coutre, S.; Fox, J.A.; Mahadocon, K.; Chen, T.; Kegley, P.; Hoch, U.; Wierda, W.G. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J. Clin. Oncol., 2010, 20, 3015-3022.
98. Chen, R.; Wierda, W.G.; Chubb, S.; Hawtin, R.E.; Fox, J.A.; Keating, M.J.; Gandhi, V. Plunkett W. Mechanism of action of SNS-032, a novel cyclindependent kinase inhibitor, in chronic lymphocytic leukemia. Blood, 2009,113, 4637-4645.
99. Conroy, A.; Stockett, D.E.; Walker, D.; Arkin, M.R.; Hoch, U.; Fox, J.A.; Hawtin, R.E. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother. Pharmacol., 2009, 64, 723-732.
100. Walsby, E.; Lazenby, M.; Pepper, C.; Burnett, A.K. The cyclin-dependent Kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia, 2011, 25, 411-419.
101. Kruse, U.; Pallasch, C.P.; Bantscheff, M.; Eberhard, D.; Frenzel, L.; Ghidelli, S.; Maier, S.K.; Werner, T.; Wendtner, C.M.; Drewes, G. Chemoproteomicsbased kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 89-31
102. Ali, M.A.; Choy, H.; Habib, A.A.; Sacha, D. SNS-032 prevents tumor cellinduced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia, 2007, 9, 370-381.
103. Bach, S.; Knockaert, M.; Reinhardt, J.; Lozach, O.; Schmitt, S.; Baratte, B.; Koken, M.; Coburn, S.P.; Tang, L.; Jiang, T.; Liang, D.C.; Galons, H.; Dierick, J.F.; Pinna, L.A.; Meggio, F.; Totzke, F.; Schächtele, C.; Lerman, A.S.; Carnero, A.; Wan, Y.; Gray, N.; Meijer, L. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem., 2005, 280, 31208-31219.
104. Hahntow, I.N.; Schneller, F.; Oelsner, M.; Weick, K.; Ringshausen, I.; Fend, F.; Peschel, C.; Decker, T. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 747-755.
105. Wesierska-Gadek, J.; Wandl, S.; Kramer, M.P.; Pickem, C.; Krystof V, Hajek, S.B. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J. Cell. Biochem., 2008, 105, 1161-1171.
106. Hahntow, I.N.; Schneller, F.; Oelsner, M.; Weick, K.; Ringshausen, I.; Fend, F.; Peschel, C.; Decker, T. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by downregulation of genes involved in transcription regulation and survival. Blood, 2005, 105, 4484-4491.
107. Rogalińska, M.; Błoński, J.Z.; Komina, O.; Góralski, P.; Zołnierczyk, J.D.; Piekarsk,i H.; Robak, T.; Kiliańska, Z.M.; Wesierska-Gadek, J. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. J. Cell. Biochem., 2010,109, 217-235.
108. Zolnierczyk, J.D.; Błoński, J.Z.; Robak, T.; Kiliańska, Z.M.; Wesierska-Gadek, J. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Ann N Y Acad Sci., 2009,1171,124-131.
109. Hahntow, I.N.; Schneller, F.; Oelsner, M.; Weick, K.; Ringshausen, I.; Fend, F.; Peschel, C.; Decker, T. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 747-755.
110. Alkan, S.; Huang, Q.; Ergin, M.; Denning, M.F.; Nand, S.; Maududi, T.; Paner, G.P.; Ozpuyan, F.; Izban, K.F. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am. J. Hematol., 2005, 79, 97-106.
111. Michie, A.M. Nakagawa, R. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia. Hematol Oncol., 2006, 24,134-138.
112. Keck, G.E.; Poudel, Y.B.; Cummins, T.J.; Rudra, A.; Covel, J.A. Total synthesis of bryostatin 1. J. Am. Chem. Soc., 2011,133, 744-747.
113. Bosco, M.C.; Rottschafer, S.; Taylor, L.S.; Ortaldo, J.R.; Longo, D.L.; Espinoza-Delgado, I. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression. Blood, 1997, 89, 3402-3411.
114. Beck, F.W.; Eilender, D.S.; Dandashi, M.H.; Siddiq, F.; Snell, D.C.; Godmere, M.A.; Al-Katib, A.M.; Mohammad, R.M. Factors affecting bryostatin 1- enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia. Int. J. Mol. Med., 2004, 14, 113-119.
115. Beck, F.W.; Eilender, D.S.; Dandashi, M.H.; Siddiq, F.; Snell, D.C.; Godmere, M.A.; Al-Katib, A.M.; Mohammad, R.M. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2- chlorodeoxyadenosine: preclinical studies. Clin. Cancer Res., 1998, 64, 445-453.
116. Ahmad, I.; Al-Katib, A.M.; Beck, F.W.; Mohammad, R.M. Sequential treat ment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report. Clin. Cancer Res., 2000, 66, 1328-1332.
117. Roberts, J.D.; Smith, M.R.; Feldman, E.J.; Cragg, L.; Millenson, M.M.; Roboz, G.J.; Honeycutt, C.; Thune, R.; Padavic-Shaller, K.; Carter, W.H.; Ramakrishnan, V.; Murgo, A.J.; Grant, S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin. Cancer Res., 2006, 12, 5809-5816.
118. Barr, P.M.; Lazarus, H.M.; Cooper, B.W.; Schluchter, M.D.; Panneerselvam, A.; Jacobberger, J.W.; Hsu, J.W.; Janakiraman, N.; Simic, A.; Dowlati, A.; Remick, S.C.Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol., 2009, 84, 484-487.
119. Chen, Y.B.; LaCasce, A.S. Enzastaurin. Expert Opin. Investig. Drugs, 2008,17, 939-944.
120. Ysebaert, L.; Morschhauser, F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opin Investig Drugs. 2011, 20, 1167-1174.
121. Graff, J.R.; McNulty, A.M.; Hanna, K.R.; Konicek, B.W.; Lynch, R.L.; Bailey, S.N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J.E.; Sams, L.; Huss, K.L.; Campbell, R.M.; Iversen, P.W.; Neubauer, B.L.; Brown, T.J.; Musib, L.; Geeganage, S.; Thornton, D. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res., 2005, 65, 7462-7469.
122. Ma, S.; Rosen, S.T. Enzastaurin. Curr Opin Oncol., 2007, 19, 590-595.
123. Wu, X.; Zhu, M.; Fletcher, J.A.; Giobbie-Hurder, A.; Hodi, F.S. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One., 2012, 7, 29622.
124. Robertson, M.J.; Kahl, B.S.; Vose, J.M.; de Vos, S.; Laughlin, M.; Flynn, P.J.; Rowland, K.; Cruz, J.C.; Goldberg, S.L.; Musib, L.; Darstein, C.; Enas, N.; Kutok, J.L.; Aster, J.C.; Neuberg, D.; Savage, K.J.; LaCasce, A.; Thornton, D.; Slapak, C.A.; Shipp, M.A.Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol., 2007, 25, 1741-1746.
125. Holler, C.; Piñón, J.D.; Denk, U.; Heyder, C.; Hofbauer, S.; Greil, R.; Egle, A. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia. Blood, 2009, 113, 2791-2794.
126. Ysebaert, L.; Morschhauser, F. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert. Opin. Investig. Drugs., 2011, 20, 1167-1174.
127. Morschhauser, F.;Seymour, J.F.; Kluin-Nelemans, H.C.; Grigg, A.; Wolf, M.; Pfreundschuh, M.; Tilly, H.; Raemaekers, J.; van 't Veer, M.B. Milpied, N.; Cartron, G.; Pezzutto, A.; Spencer, A.; Reyes, F.; Dreyling, M. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol., 2008, 19, 247-253.
128. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhart, D.J.; Milanov, Z.V.; Morrison, M.J.; Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2008, 26, 127-132.
129. Fabbro, D.; Ruetz, S.; Bodis, S.; Pruschy, M.; Csermak, K.; Man, A, Campochiaro, P.; Wood, J.; O'Reilly, T.; Meyer, T. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug. Des. 2000,15,17-28.
130. Fischer, T.; Stone, R.M.; Deangelo, D.J.; Galinsky, I.; Estey, E.; Lanza, C.; Fox, E.; Ehninger, G.; Feldman, E.J.; Schiller, G.J.; Klimek, V.M.; Nimer, S.D.; Gilliland, D.G.; Dutreix, C.; Huntsman-Labed, A.; Virkus, J.; Giles, F.J. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J. Clin. Oncol., 2010, 28, 4339-4345.
131. Ganeshaguru, K.; Wickremasinghe, R.G.; Jones, D.T.; Gordon, M.; Hart, S.M.; Virchis, A.E.; Prentice, H.G.; Hoffbrand, A.V.; Man, A.; Champain, K.; Csermak, K, Mehta, A.B. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica, 2002, 8, 167-176.
132. Virchis, A.; Ganeshaguru, K.; Hart, S.; Jones, D.; Fletcher, L.; Wright, F.; Wickremasinghe, R.; Man, A.; Csermak, K.; Meyer, T.; Fabbro, D.; Champain, K.; Yap, A.; Prentice, H.G.; Mehta A. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol. J., 2002, 3, 131-136.
133. Kruse, U.; Pallasch, C.P.; Bantscheff, M.; Eberhard, D.; Frenzel, L.; Ghidelli, S.; Maier, S.K.; Werner, T.; Wendtner, C.M.; Drewes, G. Chemoproteomicsbased kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 89-100.
134. Kantarjian, H.M.; Shah, N.P.; Cortes, J.E.; Baccarani, M.; Agarwal, M.B.; Undurraga, M.S.; Wang, J.; Kassack, Ipiña, J.J.; Kim, D.W.; Ogura, M.; Pavlovsky, C.; Junghanss, C.; Milone, J.H.; Nicolini, F.E.; Robak, T.; Van Droogenbroeck, J.; Vellenga, E.; Bradley-Garelik, M.B.; Zhu, C.; Hochhaus, A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood, 2012,119, 1123-1129.
135. Veldurthy, A.; Patz, M.; Hagist, S.; Pallasch, C.P.; Wendtner, C.M.; Hallek, M.; Krause, G. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood, 2008, 112, 1443-1452.
136. Contri, A.; Brunati, A.M.; Trentin, L.; Cabrelle, A.; Miorin, M.; Cesaro, L.; Pinna, L.A.; Zambello, R.; Semenzato, G.; Donella-Deana, A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest., 2005, 115, 369-78.
137. Amrein, P.C.; Attar, E.C.; Takvorian, T.; Hochberg, E.P.; Ballen, K.K.; Leahy, K.M.; Fisher, D.C.; Lacasce, A.S.; Jacobsen, E.D.; Armand, P.; Hasserjian, R.P.; Werner, L.; Neuberg, D.; Brown, J.R.Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer. Res., 2011,17, 2977- 2986.
138. Al-Ameri, A.M. Phase II study of dasatinib in patients with relapsed chronic lymphocytic leukemia. Blood, 2010, 116, 4488-4486.
139. Cortes, J.E.; Kantarjian, H.M.; Brümmendorf, T.H.; Kim, D.W.; Turkina, A.G.; Shen, Z.X.; Pasquini, R.; Khoury, H.J.; Arkin, S.; Volkert, A.; Besson, N.; Abbas, R.; Wang, J.; Leip, E.; Gambacorti-Passerini, C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomepositive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood, 2011,118, 4567-4576.
140. Ghosh, A.K.; Secrto, C.; Boysen, J.; Sassoon, T.; Shanafelt, T.D.; Mukhopadhyay, D.; Kay, N.E. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood, 2011, 117, 1928-1937.
141. Pignochino, Y.; Grignani, G.; Cavalloni, G.; Motta, M.; Tapparo, M.; Bruno, S.; Bottos, A.; Gammaitoni, L.; Migliardi, G.; Camussi, G.; Alberghini, M.; Torchio, B.; Ferrari, S.; Bussolino, F.; Fagioli, F.; Picci, P.; Aglietta, M. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol. Cancer, 2009, 8, 118.
142. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64,7099-7109.
143. Rini, B.I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Szczylik, C.; Hutson, T.E.; Michaelson, M.D.; Gorbunova, V.A.; Gore, M.E.; Rusakov, I.G.; Negrier, S.; Ou, Y.C.; Castellano, D.; Lim, H.Y.; Uemura, H.; Tarazi, J.; Cella, D.; Chen, C.; Rosbrook, B.; Kim, S.; Motzer, R.J. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, 2011, 378, 1931-1939.
144. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359, 378-390.
145. Messmer, D.; Fecteau, J.F.; O'Hayre, M.; Bharati, I.S.; Handel, T.M.; Kipps, T.J. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood, 2011, 117, 882-889.
146. López-Guerra, M.; Xargay-Torrent, S.; Pérez-Galán, P.; Saborit-Villarroya, I.; Rosich, L.; Villamor, N.; Aymerich, M.; Roué, G.; Campo, E.; Montserrat, E.; Colomer, D. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia, 2012, 26,1429-1432.
147. Rahmani, M.; Davis, E.M.; Bauer, C.; Dent, P.; Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 2005, 280, 35217-35227.
148. Fecteau, J.F.; Bharati, I.S.; O'hayre, M.; Handel, T.M.; Kipps, T.J.; Messmer, D. Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1). Mol. Med., 2012,18, 19-28.
149. Huber, S.; Oelsner, M.; Decker, T.; zum Büschenfelde, C.M.; Wagner, M.; Lutzny,G.; Kuhnt, T.; Schmidt, B.; Oostendorp, R.A.; Peschel, C.; Ringshausen, I. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia, 2011, 25, 838-847.
150. Yu, C.; Friday, B.B.; Lai, J.P.; Yang, L.; Sarkaria, J.; Kay, N.E. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c- Jun NH2-terminal kinase pathways. Mol. Cancer Ther., 2006, 5, 2378-2387.
151. Faivre, S., Demetri, G., Sargent, W., Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov., 2007, 6, 734-745.
152. Abrams, T.J.; Lee, L.B.; Murray, L.J.; Pryer, N.K.; Cherrington, J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther., 2003, 2, 471-478.
153. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327-337.
154. Baratte, S.; Sarati, S.; Frigerio, E.; James, C.A.; Ye, C.; Zhang, Q. Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J. Chromatogr., 2004, 1024, 87-94.
155. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J.P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol., 2006, 24, 25-35.
156. Shanafelt, T.; Zent, C.; Byrd, J.; Erlichman, C.; Laplant, B.; Ghosh, A.; Call, T.; Villalona-Calero, M.; Jelinek, D.; Bowen, D.; Laumann, K.; Wu, W.; Hanson, C.; Kay, N. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 2010, 51, 2222-2229.
157. Wedge, S.R.; Ogilvie, D.J.; Dukes, M.; Kendrew, J.; Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res., 2002, 62, 4645-4655.
158. Kummar, S.; Gutierrez, M.E.; Chen, A.; Turkbey, I.B.; Allen, D.; Horneffer, Y.R.; Juwara, L.; Cao, L.; Yu, Y.; Kim, Y.S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A.J.; Collins, J.; Doroshow, J.H. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur. J. Cancer., 2011, 47, 997-1005.
159. Holden, S.N.; Eckhardt, S.G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M.A.; Wheeler, C.; Barge, A.; Hurwitz, H.I. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors, Ann. Oncol., 2005,16, 1391-1397.
160. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.;Carlomagno, F.; Veneziani, B.M.; Fontanini, G.; Bianco, A.R.; Tortora, G.; Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9, 1546-1556.
161. Brave, S.R.; Odedra, R.; James, N.H.; Smith, N.R.; Marshall, G.B.; Acheson, K.L.; Baker, D.; Howard, Z.; Jackson, L.; Ratcliffe, K.; Wainwright, A.; Lovick, S.C.; Hickinson, D.M.; Wilkinson, R.W.; Barry, S.T.; Speake, G.; Ryan, A.J. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int. J. Oncol. 2011, 39, 271-8.
162. Morabito, A.; Piccirillo, M.C.; Falasconi, F.; De Feo, G.; Del Giudice, A.; Bryce, J.; Di Maio, M.; De Maio, E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist, 2009,14, 378-390.
163. Natale, R.B.; Bodkin, D.; Govindan, R. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. J. Clin. Oncol., 2006, 24, 7000-7042.
164. Heymach, J.V.; Johnson, B.E.; Prager, D.; Csada, E.; Roubec, J.; Pesek, M.; Spásová, I.; Belani, C.P.; Bodrogi, I.; Gadgeel, S.; Kennedy, S.J.; Hou, J.; Herbst, R.S. Randomized placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small cell lung cancer. J. Clin. Oncol., 2007, 25, 4270-4277.
165. Jia, H.Y.; Wu, J.X.; Zhu, X.F.; Chen, J.M.; Yang, S.P.; Yan, H.J.; Tan, L.; Zeng, Y.X.; Huang, W. ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leuk. Res., 2009, 33, 1512-1519.
166. Lee, S.H.; Lopes de Menezes, D.; Vora, J.; Harris, A.;Ye, H.; Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S.L.; Gelb, A.B.; Heise, C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res., 2005,11, 3633-3641.
167. Trudel, S.; Li, Z.H.; Wei, E.; Wiesmann, M.; Chang, H.; Chen, C.; Reece, D.; Heise, C.; Stewart, A.K. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 2005,105, 2941-2948.
168. Kruse, U.; Pallasch, C.P.; Bantscheff, M.; Eberhard, D.; Frenzel, L.; Ghidelli, S.; Maier, S.K.; Werner, T.; Wendtner, C.M.; Drewes, G. Chemoproteomicsbased kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 89-100.
169. Motiwala, T.; Datta, J.; Kutay, H.; Roy, S.; Jacob, S.T. Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib. J. Cell. Biochem., 2010, 110, 846-856.
170. Sloan, B.; Scheinfeld, N.S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs, 2008, 9, 1324-1335.
171. Kumar, R.; Knick, V.B.; Rudolph, S.K.; Johnson, J.H.; Crosby, R.M.; Crouthamel, M.C.; Hopper, T.M.; Miller, C.G.; Harrington, L.E.; Onori, J.A.; Mullin, R.J.; Gilmer, T.M.; Truesdale, A.T.; Epperly, A.H.; Boloor, A.; Stafford, J.A.; Luttrell, D.K.; Cheung, M. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther., 2007, 6, 2012-2021.
172. Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schöffski, P.; Collin, F.; Pandite, L.; Marreaud, S.; De Brauwer, A.; van Glabbeke M, Verweij J, Blay J.Y. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancersoft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol., 2009, 27, 3126-3132.
173. Iwamoto, F.M.; Lamborn, K.R.; Robins, H.I.; Mehta, M.P.; Chang, S.M.; Butowski, N.A.; Deangelis, L.M.; Abrey, L.E.; Zhang, W.T.; Prados, M.D.; Fine, H.A. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro. Oncol., 2010, 12, 855-861.
174. Prince, H.M.; Hönemann, D.; Spencer, A.; Rizzieri, D.A.; Stadtmauer, E.A.; Roberts, A.W.; Bahlis, N.; Tricot, G.; Bell, B.; Demarini, D.J.; Benjamin Suttle, A.; Baker, K.L.; Pandite, L.N. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood, 2009, 113, 4819-4820.
175. Paesler, J.; Gehrke, I.; Gandhirajan, R.K.; Filipovich, A.; Hertweck, M.; Erdfelder, F.; Uhrmacher, S.; Poll-Wolbeck, S.J.; Hallek, M.; Kreuzer, K.A. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin. Cancer Res., 2010, 16, 3390-3398.
176. Kelly, R.J.; Rixe, O. Axitinib (AG-013736). Rec. Res. Cancer Res., 2010, 184, 33-44.
177. Wilmes, L.J.; Pallavicini, M.G.; Fleming, L.M.; Gibbs, J.; Wang, D.; Li, K.L.;Partridge, S.C.; Henry, R.G.; Shalinsky, D.R.; Hu-Lowe, D.; Park, J.W.; McShane, T.M.; Lu, Y.; Brasch, R.C.; Hylton, N.M. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrastenhanced magnetic resonance imaging. Magn. Reson. Imaging, 2007, 25, 319-327.
178. Hu-Lowe, D.D.; Zou, H.Y.; Grazzini, M.L.; Hallin, M.E.; Wickman, G.R.; Amundson, K.; Chen, J.H.; Rewolinski, D.A.; Yamazaki, S.; Wu, E.Y.; McTigue, M.A.; Murray, B.W.; Kania, R.S.; O'Connor, P.; Shalinsky, D.R.; Bender, S.L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res., 2008, 14, 7272-7283.
179. Choueiri, T.K. Axitinib, a novel antiangiogenic drug with promising activity in various solid tumors. Curr. Opin. Investig. Drugs, 2008, 9, 658-671.
180. Ciraolo, E.; Perino, A.; Hirsch, E. Measuring PI3K lipid kinase activity. Methods Mol Biol. 2012, 795, 55-67.
181. Okkenhaug, K.; B. Vanhaesebroeck. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol, 2003, 3, 317-330.
182. Herman, S.E.; Gordon, A.L.; Wagner, A.J.; Heerema, N.A.; Zhao, W.; Flynn, J.M.; Jones, J.; Andritsos, L.; Puri, K.D.; Lannutti, B.J.; Giese, N.A.; Zhang, X.; Wei, L.; Byrd, J.C.; Johnson, A.J. Phosphatidylinositol 3-kinasedelta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, 2010, 116, 2078-2088.
183. Park, E.; Park, J.; Han, S.W.; Im, S.A.; Kim, T.Y.; Oh, D.Y.; Bang, Y.J. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int. J. Oncol., 2012, 40, 1259-1266.
184. Dienstmann, R.; Rodon, J.; Markman, B.; Tabernero, J. Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat Anticancer Drug Discov., 2011, 6, 210-236.
185. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7, 606-619.
186. Hay, N.The Akt-mTOR tango and its relevance to cancer. Cancer Cell., 2005, 8, 179-183.
187. Castillo, J.J.; Furman, M.; Winer, E.S. CAL-101: a phosphatidylinositol- 3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012, 21, 15-22.
188. Meadows, S.A.; Vega, F.; Kashishian, A.; Johnson, D.; Diehl, V.; Miller, L.L.;Younes, A.; Lannutti, B.J. PI3Kδ inhibitor, GS- 1101(CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood, 2012, 119, 1897-900.
189. Hoellenriegel, J.; Meadows, S.A.; Sivina, M.; Wierda, W.G.; Kantarjian, H.; Keating, M.J.; Giese, N.; O'Brien, S.; Yu, A.; Miller, L.L.; Lannutti, B.J.; Burger, J.A. The phosphoinositide 3'- kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood, 2011, 118, 3603-3612.
190. Lannutti, B.J.; Meadows, S.A.; Herman, S.E.; Kashishian, A.; Steiner, B.; Johnson, A.J.; Byrd, J.C.; Tyner, J.W.; Loriaux, M.M.; Deininger, M.; Druker, B.J.; Puri, K.D.; Ulrich, R.G.; Giese, N.A. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117, 591-594.
191. Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012,7,26-33.
192. Schmidt-Kittler, O.; Zhu, J.; Yang, J.; Liu, G.; Hendricks, W.; Lengauer, C.;Gabelli, S.B.; Kinzler, K.W.;Vogelstein, B.; Huso, D.L.;Zhou, S. PI3Kα inhibitors that inhibit metastasis. Oncotarget, 2010, 1, 339-348.
193. Maira, S.M.; Pecchi, S.; Huang, A.; Burger, M.; Knapp, M.; Sterker, D.; Schnell, C.; Guthy, D.; Nagel, T.; Wiesmann, M.; Brachmann, S.; Fritsch, C.; Dorsch, M.; Chène, P.; Shoemaker, K.; De Pover, A.; Menezes, D.; Martiny-Baron, G.; Fabbro, D.; Wilson, C.J.; Schlegel, R.; Hofmann, F.; García-Echeverría, C.; Sellers, W.R.; Voliva, C.F. Identification and characterization of NVP-BKM120, an orally available pan class I PI3-Kinase inhibitor. Mol. Cancer Ther., 2011, 11, 317-328.
194. Zheng, Y.; Yang, J.; Qian, J.; Zhang, L.; Lu, Y.; Li, H.; Lin, H.; Lan, Y.; Liu, Z.; He, J.; Hong, S.; Thomas, S.; Shah, J.; Baladandayuthapani, V.; Kwak, L.W.;Yi, Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J. Mol. Med. (Berl), 2011, 90, 695-706.
195. Sutherlin, D.P.;Bao, L.; Berry, M.; Castanedo, G.; Chuckowree, I.; Dotson, J.; Folks, A.; Friedman, L.; Goldsmith, R.; Gunzner, J.; Heffron, T.; Lesnick, J.; Lewis, C.;Mathieu, S.; Murray, J.; Nonomiya, J.; Pang, J.; Pegg, N.; Prior, W.W.; Rouge, L.; Salphati, L.; Sampath, D.; Tian, Q.; Tsui, V.; Wan, N.C.; Wang, S.; Wei, B.; Wiesmann, C.; Wu, P.; Zhu, B.Y.; Olivero, A. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem., 2011, 54, 7579-7587.
196. Hoeflich, K.P.; Merchant, M.; Orr, C.;Chan, J.; Den Otter, D.; Berry, L.; Kasman, I.; Koeppen, H.; Rice, K.; Yang, N.Y.; Engst, S.; Johnston, S.; Friedman, L.S.; Belvin, M. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res., 2012, 72, 210-219.
197. Salphati, L.; Wong, H.; Belvin, M.; Bradford, D.; Edgar, K.A.; Prior, W.W.; Sampath, D.; Wallin, J.J.; Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor gdc-0941. Drug. Metab. Dispos., 2010, 38, 1436-1442.
198. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.; Friedman, L.S.; Hayes, A.; Hancox, T.C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A.G.; Pang, J.;Patel, S.; Pergl-Wilson, G.H.; Raynaud, F.I.; Robson, A.; Saghir, N.; Salphat, L.; Sohal, S.; Ultsch, M.H.; Valenti, M.; Wallweber, H.J.; Wan, N.C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M.J.; Shuttleworth, S.J. The identification of 2-(1H-indazol-4-yl)-6- 4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51, 5522-5532.
199. Wullschleger, S.; García-Martínez, J.M.; Duce, S.L.; Quantitative, M.R.;I establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma. Anticancer Res., 2012, 32, 415-20.
200. García-Martínez, J.M.; Wullschleger, S.; Preston, G.; Guichard, S.; Fleming, S.; Alessi, D.R.; Duce, SL. Effect of PI3K-and mTORspecific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKBI-deficient mice. Br J Cancer, 2011, 104, 1116-1125.
201. Carnero, A. Novel inhibitors of the PI3K family. Expert Opin. Investig. Drugs., 2009, 18, 1265-1277.
202. Harvey, R.D.; Lonial, S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol., 2007, 3, 639-647.
203. Ozbay, T.; Durden, D.L.; Liu, T.; O'Regan, R.M.; Nahta, R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother. Pharmacol., 2010, 65, 697-706.
204. Garlich, J.R.; De, P.; Dey, N.; Su, J.D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G.B.; Kundra, V.; Shu, H.K.; Peng, Q.; Durden, D.L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res., 2008, 68, 206-215.
205. Maira, S.M.; Pecchi, S.; Huang, A.; Burger, M.; Knapp, M.; Sterker, D.; Schnell, C.; Guthy, D.; Nagel, T.; Wiesmann, M.; Brachmann, S.; Fritsch, C.; Dorsch, M.; Chène, P.; Shoemaker, K.; De Pover, A.; Menezes, D.; Martiny-Baron, G.; Fabbro, D.; Wilson, C.J.; Schlegel, R.; Hofmann, F.; García-Echeverría, C.; Sellers, W.R.; Voliva, C.F. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase Inhibitor. Mol. Cancer Ther., 2012, 11, 317-628.
206. Baumann, P.; Mandl-Weber, S.; Oduncu, F.; Schmidmaier, R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp. Cell. Res., 2009, 315, 485-497.
207. Hernlund, E.; Olofsson, M.H.; Fayad, W.; Fryknäs, M.; Lesiak-Mieczkowska, K.; Zhang, X.; Brnjic, S.; Schmidt, V.; D'Arcy, P.; Sjöblom, T.; Milito, A.D.; Larsson, R.; Linder, S. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. Eur. J. Cancer., 2012, 48, 396-406.
208. Schult, C.; Dahlhaus, M.; Glass, A.; Fischer, K.; Lange, S.; Freund, M.; Junghanss, C.The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res. 2012, 32, 463-744.
209. Roper, J.; Richardson, M.P.; Wang, W.V.; Richard, L.G.; Chen, W.; Coffee, E.M.;Sinnamon, M.J.; Lee, L.; Chen, P.C.; Bronson, R.T.; Martin, E.S.; Hung, K.E. The dual PI3K/mTOR inhibitor NVP- BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One., 2011, 6, 25132.
210. Garcia-Echeverria, C.; Sellers, W.R.; Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27, 5511-5526.
211. Chakrabarty, A.; Sánchez, V.; Kuba, M.G.; Rinehart, C.; Arteaga, C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U S A, 2012, 109, 2718-2723.
212. Sutherlin, D.P.; Bao, L.; Berry, M.; Castanedo, G.; Chuckowree, I.; Dotson, J.;Folks, A.; Friedman, L.; Goldsmith, R.; Gunzner, J.;Heffron, T.; Lesnick, J.; Lewis, C.; Mathieu, S.; Murray, J.; Nonomiya, J.; Pang, J.; Pegg, N.; Prior, W.W.; Rouge, L.; Salphati, L.; Sampath, D.;Tian, Q.; Tsui, V.; Wan,N.C.; Wang, S.; Wei, B.; Wiesmann, C.; Wu, P.; Zhu, B.Y.; Olivero, A. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC- 0980) for the treatment of cancer. J. Med. Chem., 2011, 54,7579-7587.
213. Wallin, J.J.; Edgar, K.A.; Guan, J.; Berry, M.; Prior, W.W.; Lee, L.; Lesnick, J.D.; Lewis, C.; Nonomiya, J.; Pang, J.; Salphati, L.; Olivero, A.G.; Sutherlin, D.P.; O'Brien, C.; Spoerke, J.M.; Patel, S.; Lensun, L.; Kassees, R.; Ross, L.; Lackner, M.R.; Sampath, D.; Belvin, M.; Friedman, L.S. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther., 2011, 10, 2426-2436.
214. Williams, R.; Baker, A.F.; Ihle, N.T.; Winkle, A.R.; Kirkpatrick, L.; Powis, G.The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer. Chemother. Pharmacol., 2006, 58, 444-50.
215. Ihle, N.T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M.I.; Paine-Murrieta, G.;Minion, D.J.; Halter, R.J.; Wipf, P.; Abraham, R.;Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer. Ther., 2004, 3, 763-772.
216. Ihle, N.T.; Lemos, R.; Jr, Wipf, P.; Yacoub, A.; Mitchell, C.; Siwak, D.; Mills, G.B.; Dent, P.; Kirkpatrick, D.L.; Powis, G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res., 2009, 69, 143-150.
217. Dehnhardt, C.M.; Venkatesan, A.M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-Kaloustian, S.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Chaudhary, I.; Yu,K.; Gibbons, J.; Abraham, R.;Mansour, T.S. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem., 2010, 28,798-810.
218. Mallon, R.; Hollander,I.; Feldberg, L.; Lucas, J.; Soloveva, V.; Venkatesan, A.; Dehnhardt, C.; Delos Santos, E,; Chen, Z.;Dos Santos, O.; Ayral-Kaloustian, S.; Gibbons, J. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol. Cancer Ther., 2010, 9, 976-984.
219. Dehnhardt, C.M; Venkatesan, A.M.; Chen, Z; Delos-Santos, E.; Ayral-Kaloustian, S.; Brooijmans, N.; Yu, K.; Hollander, I.; Feldberg, L.; Lucas, J.; Mallon, R. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors. Bioorg. Med. Chem. Lett., 2011, 21,4773-4778.
220. Mallon, R.; Feldberg, L.R.; Lucas, J.; Chaudhary, I.; Dehnhardt, C.; Santos, E.D.; Chen, Z.; dos Santos, O.; Ayral-Kaloustian, S.; Venkatesan, A.; Hollander, I. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin. Cancer Res., 2011, 17, 3193-3203.